Together with evidence from prior studies, our results suggest that mTOR inhibitors should be the agents of choice in patients with PEComas, considering the better safety profile of these agents compared with cytotoxic chemotherapy. Here, MTOR is linked to neoplasm with perivascular epithelioid cell differentiation.